第73回千葉医学会総会記事

Microarray data of genes with lower expression levels (<0.74, p < 0.05) in 35S:ROXY19 plants as compared to control plants and their response to TIBA in the Col-0 background. The table contains the gene identity (AGI), description, the mean expression values of four independent biological replicates of the genotypes Col-0 and 35S:ROXY19#8, the ratios (FC, fold changes, log2) of the transcript levels in the transgenic line with respect to Col-0 and the corresponding p-values, the ratios between Col-0 treated with 0.1 % DMSO and Col-0 treated with 0.1 mM TIBA/0.1 % DMSO and the corresponding p-values. Since the microarray analysis of the TIBA-treated plants was performed with the Affimetrix ATH1 gene chip, the list contains 301 and not 321 genes. Genes that are not induced by TIBA are shown in light grey. FC, fold changes. For TIBA induction, plants were grown for six to seven weeks on steamed soil (Archut, Fruhstorfer Erde, T25, Str1fein) in growth chambers with light intensity at 37 to 45 μmol photons m−2 s−1 at 22 °C and 60 % humidity. Eight plants were sprayed with either 0.1 mM TIBA/0.1 % DMSO or with 0.1 % DMSO and leaves were harvested after eight h. The experiment was repeated three times. (XLSX 205 kb

Additional file 2: Table S2. of Ectopically expressed glutaredoxin ROXY19 negatively regulates the detoxification pathway in Arabidopsis thaliana

Microarray data of genes with lower expression levels (FC < 0.74, p < 0.05) in 35S:ROXY19 plants as compared to control plants. The table contains the gene identity (AGI), description, the mean expression values of four independent biological replicates of the genotypes Col-0, 35S:GRXC2, 35S:ROXY19 SSMS , 35S:ROXY19#8 and 35S:ROXY19#12, and the ratios (FC, fold changes, log2) of the transcript levels in the transgenic lines with respect to Col-0 and the corresponding p-values. (XLSX 305 kb

High ABCG4 Expression Is Associated with Poor Prognosis in Non-Small-Cell Lung Cancer Patients Treated with Cisplatin-Based Chemotherapy

<div><p>ATP-binding cassette (ABC) transporters are associated with poor response to chemotherapy, and confer a poor prognosis in various malignancies. However, the association between the expression of the ABC sub-family G member 4 (ABCG4) and prognosis in patients with non-small-cell lung cancer (NSCLC) remains unclear. NSCLC tissue samples (n = 140) and normal lung tissue samples (n = 90) were resected from patients with stage II to IV NSCLC between May 2004 and May 2009. ABCG4 mRNA and protein expressions were detected by RT-PCR, western blot, and immunohistochemistry. Patients received four cycles of cisplatin-based post-surgery chemotherapy and were followed up until May 31^st, 2014. ABCG4 positivity rate was higher in NSCLC than in normal lung tissues (48.6% <i>vs</i>. 0%, <i>P</i><0.001) and ABCG4 expression was significantly associated with poor differentiation, higher tumor node metastasis (TNM) stage, and adenocarcinoma histological type (all <i>P</i><0.001). Univariate (HR = 2.284, 95%CI: 1.570–3.324, <i>P</i><0.001) and multivariate (HR = 2.236, 95%CI: 1.505–3.321, <i>P</i><0.001) analyses showed that ABCG4 expression was an independent factor associated with a poor prognosis in NSCLC. Patients with ABCG4-positive NSCLC had shorter median survival than ABCG4-negative NSCLC (20.1 <i>vs</i>. 43.2 months, <i>P</i><0.001). The prognostic significance of ABCG4 expression was apparent in stages III and IV NSCLC. In conclusion, high ABCG4 expression was associated with a poor prognosis in patients with NSCLC treated with cisplatin-based chemotherapy.</p></div

Correlation between ABCG4 expression status and prognosis of NSCLC patients treated with cisplatin-based chemotherapy.

<p>(A) Kaplan-Meier curves were plotted to determine cumulative survival rate of NSCLC patients based on ABCG4 expression (negative <i>vs</i>. positive). (B) Kaplan-Meier curves were plotted to determine cumulative survival rate of NSCLC patients based on tumor node metastasis (TNM) stage (II <i>vs</i>. III <i>vs</i>. IV). (C) Kaplan-Meier curves were plotted to determine cumulative survival rate of NSCLC patients based on differentiation (poorly <i>vs</i>. moderately/well). (D) Kaplan-Meier curves were plotted to determine cumulative survival rate of NSCLC patients with TNM stage II based on ABCG4 expression (negative <i>vs</i>. positive). (E) Kaplan-Meier curves were plotted to determine cumulative survival rate of NSCLC patients with TNM stage III based on ABCG4 expression (negative <i>vs</i>. positive). (F) Kaplan-Meier curves were plotted to determine cumulative survival rate of NSCLC patients with TNM stage IV based on ABCG4 expression (negative <i>vs</i>. positive). Negative:-; Positive: +, ++ and +++.</p

ABCG4 protein expression in NSCLC and normal lung tissues was detected by immunohistochemistry.

<p>(A) Normal lung tissue; (B) Negative (-) staining of ABCG4 in NSCLC tissue; (C) Weakly positive (+) staining of ABCG4 in NSCLC tissue; (D) Moderately positive (++) staining of ABCG4 in NSCLC tissue; (E) Strongly positive (+++) staining of ABCG4 in NSCLC tissue; (F) Immunohistochemistry showing ABCG4-negative staining in NSCLC tissues (++) using ABCG4 blocking peptide. Magnification: 200×.</p

ATP-binding cassette sub-family G member 4 (ABCG4) mRNA expression was detected in non-small-cell lung cancer (NSCLC) (n = 14) and normal lung (n = 2) tissues by reverse transcription-polymerase chain reaction (RT-PCR).

<p>β-actin was used as an internal reference. M: marker. (<b>A)</b> Lane 1: positive control (A549-ABCG4). Lanes 2–3: normal lung tissues (NORM) (n = 2); <b>(B)</b> NSCLC tissues (NSCLC) (n = 14, lanes 1–14).</p